Studies on pain control in musculoskeletal chronic pain diseases.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031190172

Enrollment

240

Registered

2020-01-06

Start date

2020-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical spondylotic myelopathy, Lumbar disc herniation, Lumber spinal canal stenosis, Carpal tunnel Cervical spondylotic myelopathy, Lumbar disc herniation, Lumber spinal canal stenosis, Carpal tunnel syndrome, Osteoarthritis od the hip, Osteoarthritis of the knee, Chronic low back pain.

Interventions

To administer pregabalin, mirogabalin or duloxetine hfor 5 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who were diagnosed with cervical spondylotic myelopathy, Lumbar disc herniation, Lumber spinal canal stenosis, Carpal tunnel syndrome, Osteoarthritis od the hip, Osteoarthritis of the knee or Chronic low back pain and his symptoms continue more than three months. The patients who have not received medication for neurological disease with the exception of Cervical spondylotic myelopathy, Lumbar disc herniation, Lumber spinal canal stenosis, Carpal tunnel syndrome, Osteoarthritis od the hip, Osteoarthritis of the knee or Chronic low back pain and his symptoms continue more than three months. The patients who have not received medication for a mental disorder. The patients who have written consent to participate in this study.

Exclusion criteria

Exclusion criteria: The patients who were diagnosed with two or more in cervical spondylotic myelopathy, Lumbar disc herniation, Lumber spinal canal stenosis, Carpal tunnel syndrome, Osteoarthritis od the hip, Osteoarthritis of the knee or Chronic low back pain and his symptoms continue more than three months. The patient who should not be administered such drugs. The patient who should not take an MRI. The patient who has renal dysfunction (creatinine clearance >60mL/min) The patient who is considered by a doctor not to participate in this study.

Design outcomes

Primary

Measure	Time frame
Assessment of CNS activity	—

Secondary

Measure	Time frame
Assessment of pain, psychology, QOL, and function.	—

Contacts

Public ContactHitoshi Shitara

Gunma University Hospital

hshitara@gunma-u.ac.jp+81-27-220-8269

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026